HPV and Cervical Cancer: Updates on an Established Relationship

References

• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55(2): 74–108.
   Web of Science ®Google Scholar
• Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 1999; 83(1): 18–29.
   PubMed Web of Science ®Google Scholar
• Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005; 55(1): 10–30.
   PubMed Web of Science ®Google Scholar
• de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology. 2004; 324(1): 17–27.
   PubMed Web of Science ®Google Scholar
• Schiffman M, Castle PE. Human papillomavirus: epidemiology and public health. Arch Pathol Lab Med. 2003; 127(8): 930–934.
   PubMed Web of Science ®Google Scholar
• Munoz N, Bosch FX, de Sanjose S, et al; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348(6): 518–527.
   PubMed Web of Science ®Google Scholar
• Bosch FX, Burchell AN, Schiffman M, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine. 2008; 26(suppl 10): K1–K16.
   PubMed Web of Science ®Google Scholar
• de Sanjosé S, Diaz M, Castellsagué X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007; 7(7): 453–459.
   PubMed Web of Science ®Google Scholar
• Schiffman MH. Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst. 1992; 84(6): 394–398.
   Google Scholar
• Kjaer SK, Chackerian B, van den Brule AJ, et al. High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse). Cancer Epidemiol Biomarkers Prev. 2001; 10(2): 101–106.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Genital HPV infection—CDC fact sheet. Atlanta, GA: Centers for Disease Control and Prevention; April 2008. http://www.cdc.gov/std/HPV/STDFact-HPV.htm. Accessed October 29, 2008.
   Google Scholar
• World Health Organization. WHO HPV Information Centre, www.who.int/hpvcentre/statistics/dynamic/ico/SummaryReportsSelect.cfin. Accessed September 28, 2008.
   Google Scholar
• Herrero R, Brinton LA, Reeves WC, et al. Sexual behavior, venereal diseases, hygiene practices, and invasive cervical cancer in a high-risk population. Cancer. 1990; 65(2): 380–386.
   PubMed Web of Science ®Google Scholar
• Ursin G, Peters RK, Henderson BE, d'Ablaing G 3rd, Monroe KR, Pike MC. Oral contraceptive use and adenocarcinoma of cervix. Lancet. 1994; 344(8934): 1390–1394.
   Google Scholar
• Durst M, Gissmann L, Ikenberg H, zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA. 1983; 80(12): 3812–3815.
   PubMed Web of Science ®Google Scholar
• Schiffman MH, Bauer HM, Hoover RN, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst. 1993; 85(12): 958–964.
   PubMed Web of Science ®Google Scholar
• Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002; 55(4): 244–265.
   PubMed Web of Science ®Google Scholar
• Mougin C, Daistein V, Prétet JL, Gay C, Schaal JP, Riethmuller D. Epidemiology of cervical papillomavirus infections. Recent knowledge. Presse Med. 2001; 30(20): 1017–1023.
   PubMed Web of Science ®Google Scholar
• Fan T, Lu H, Hu H, et al. Inhibition of apoptosis in chlamydia-infected cells: blockade of mitochondrial cytochrome c release and caspase activation. J Exp Med. 1998; 187(4): 487–196.
   PubMed Web of Science ®Google Scholar
• Hagensee ME, Cameron JE, Leigh JE, Clark RA. Human papillomavirus infection and disease in HIV-infected individuals. Am J Med Sci. 2004; 328(1): 57–63.
   Google Scholar
• Shannon J, Thomas DB, Ray RM, et al. Dietary risk factors for invasive and in-situ cervical carcinomas in Bangkok, Thailand. Cancer Causes Control. 2002; 13(8): 691–699.
   PubMed Web of Science ®Google Scholar
• Hernandez BY, McDuffie K, Wilkens LR, Kamemoto L, Goodman MT. Diet and premalignant lesions of the cervix: evidence of a protective role for folate, riboflavin, thiamin, and vitamin B12. Cancer Causes Control. 2003; 14(9): 859–870.
   Google Scholar
• Tjalma WA, Van Waes TR, Van den Eeden LE, Bogers JJ. Role of human papillomavirus in the carcinogenesis of squamous cell carcinoma and adenocarcinoma of the cervix. Best Pract Res Clin Obstet Gynaecol. 2005; 19(4): 469–483.
   Google Scholar
• Pinto AP, Tulio S, Cruz OR. HPV cofactors in cervical carcinogenesis. Rev Assoc Med Bras. 2002; 48(1): 73–78.
   Google Scholar
• Moberg M, Gustavsson I, Gyllensten U. Type-specific associations of human papillomavirus load with risk of developing cervical carcinoma in situ. Int J Cancer. 2004; 112(5): 854–859.
   Google Scholar
• Lefevre J, Hankins C, Money D, Rachlis A, Pourreaux K, Coutlée F; Canadian Women's HIV Study Group. Human papillomavirus type 16 viral load is higher in human immunodeficiency virus-seropositive women with high-grade squamous intraepithelial lesions than in those with normal cytology smears. J Clin Microbiol. 2004; 42(5): 2212–2215.
   Google Scholar
• Hopman AH, Smedts F, Dignef W, et al. Transition of high-grade cervical intraepithelial neoplasia to micro-invasive carcinoma is characterized by integration of HPV 16/18 and numerical chromosome abnormalities. J Pathol. 2004; 202(1): 23–33.
   Google Scholar
• Scully C, Field JK, Tanzawa H. Genetic aberrations in oral or head and neck squamous cell carcinoma (SCCHN): 1. Carcinogen metabolism, DNA repair and cell cycle control. Oral Oncol. 2000; 36(3): 256–263.
   Google Scholar
• Roden RB, Kirnbauer R, Jenson AB, Lowy DR, Schiller JT. Interaction of papillomaviruses with the cell surface. J Virol. 1994; 68(11): 7260–7266.
   Google Scholar
• Galloway DA. Papillomavirus vaccines in clinical trials. Lancet Infect Dis. 2003; 3(8): 469–175.
   PubMed Web of Science ®Google Scholar
• Richart RM, Barron BA. A follow-up study of patients with cervical dysplasia. Am J Obstet Gynecol. 1969; 105(3): 386–393.
   PubMed Web of Science ®Google Scholar
• Bergström R, Sparén P, Adami HO. Trends in cancer of the cervix uteri in Sweden following cytological screening. Br J Cancer. 1999; 81 (1): 159–166.
   PubMed Web of Science ®Google Scholar
• Pak SC, Martens M, Bekkers R, et al. Pap smear screening history of women with squamous cell carcinoma and adenocarcinoma of the cervix. Aust N Z J Obstet Gynaecol. 2007; 47(6): 504–507.
   Google Scholar
• Sherman ME, Kelly D. High-grade squamous intraepithelial lesions and invasive carcinoma following the report of three negative Papanicolaou smears: screening failures or rapid progression? Mod Pathol. 1992; 5(3): 337–342.
   Google Scholar
• Renshaw AA, Bellerose B, DiNisco SA, Minter LJ, Lee KR. False negative rate of cervical cytologic smear screening as determined by rapid rescreening. Acta Cytol. 1999; 43(3): 344–350.
   Google Scholar
• Kulasingam SL, Hughes JP, Kiviat NB, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA. 2002; 288(14): 1749–1757.
   PubMed Web of Science ®Google Scholar
• Ferris DG, Wright TC Jr, Litaker MS, et al. Triage of women with ASCUS and LSIL on Pap smear reports: management by repeat Pap smear, HPV DNA testing, or colposcopy? J Fam Pract. 1998; 46(2): 125–134.
   Google Scholar
• Biscotti CV, O'Brien DL, Gero MA, Gramlich TL, Kennedy AW, Easley KA. Thin-layer Pap test vs conventional Pap smear: Analysis of 400 split samples. J Reprod Med. 2002; 47(1): 9–13.
   Google Scholar
• Goldie SJ, Gaffikin L, Goldhaber-Feibert JD; Alliance for Cervical Cancer Prevention Cost Working Group. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med. 2005; 353(20): 2158–2168.
   Google Scholar
• Siebert U, Sroczynski G, et al. New cervical cancer screening technologies are cost effective for screening intervals of 3 years. Annual Meeting of the International Society of Technology Assessment in Health Care. 2002; 18: Ab 282.
   Google Scholar
• Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Canadian Cervical Cancer Screening Trial Study Group. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Eng J Med. 2007; 357(16): 1579–1588.
   PubMed Web of Science ®Google Scholar
• Cox T, Cuzick J. HPV DNA testing in cervical cancer screening: from evidence to policies. Gynecol Oncol. 2006; 103(1): 8–11.
   Google Scholar
• Goldie SJ, Kim JJ, Wright TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol. 2004; 103(4): 619–631.
   PubMed Web of Science ®Google Scholar
• Vassilakos P, Petignat P, Boulvain M, Campana A. Primary screening for cervical cancer precursors by the combined use of liquid-based cytology, computer-assisted cytology and HPV DNA testing. Br J Cancer. 2002; 86(3): 382–388.
   Google Scholar
• Cuzick J, Arbyn M, Sankaranarayanan R, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine. 2008; 26(suppl 10): K29–K41.
   PubMedGoogle Scholar
• Naucler P, Ryd W, Törnberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007; 357(16): 1650–1653.
   Google Scholar
• Bulkmans NW, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007; 370(9601): 1764–1772.
   PubMed Web of Science ®Google Scholar
• Koutsky LA, Ault KA, Wheeler CM, et al; Proof of Principle Study Investigators. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002; 347(21): 1645–1651.
   PubMed Web of Science ®Google Scholar
• Harper D, Franco EL, Wheeler CM; HPV Vaccine Study Group. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006; 367(9518): 1247–1255.
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RL, Petta CA. High sustained efficacy of a prophylactic quadrivalent human papilloma virus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006; 95(11): 1459–1466.
   PubMed Web of Science ®Google Scholar
• Govan VA. A novel vaccine for cervical cancer: quadrivalent human papillomavirus (types 6,11,16and 18) recombinant vaccine (Gardasil). Ther Clin Risk Manag. 2008; 4(1): 65–70.
   PubMedGoogle Scholar
• Paavonen J, Jenkins D, Bosch FX, et al; HPV PATRICIA Study Group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007; 369(9580): 2161–2170.
   PubMed Web of Science ®Google Scholar
• Hildesheim A, Herrero R, Wacholder S, et al; Costa Rican HPV Vaccine Trial Group. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA. 2007: 298(7): 743–753.
   PubMed Web of Science ®Google Scholar
• Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med. 2008; 359(8): 821–832.
   PubMed Web of Science ®Google Scholar